Sanofi filings document a foreign biopharmaceutical issuer whose American depositary shares represent interests in ordinary shares. Its SEC record includes Form 6-K reports and Form 20-F annual reporting that incorporate parent-company press releases, financial reports, governance materials and ADR-related disclosure.
Sanofi’s filings cover operating results, research and development spending, product and pipeline updates, regulatory approvals and designations, and therapeutic areas such as immunology, vaccines, rare diseases, oncology, respiratory disease and diabetes. They also document bond issuance under its Euro Medium Term Note programme, share buyback activity, annual meeting resolutions, board and executive appointments, risk factors and capital-structure matters.
Sanofi reported the issuance of multiple U.S. dollar notes on November 3, 2025, totaling $3,000,000,000 in principal. The company sold $500,000,000 floating rate notes due November 3, 2027, $500,000,000 floating rate notes due November 3, 2028, $400,000,000 fixed rate notes due November 3, 2027, $400,000,000 fixed rate notes due November 3, 2028, and $1,200,000,000 fixed rate notes due November 3, 2032.
The report is incorporated by reference into Sanofi’s Form F-3 (No. 333-278506). Exhibits include the underwriting agreement with Barclays Capital Inc., BNP Paribas Securities Corp., BofA Securities, Inc., J.P. Morgan Securities LLC, Morgan Stanley & Co. LLC, MUFG Securities Americas Inc., and Natixis Securities Americas LLC; an indenture with Deutsche Bank Trust Company Americas as trustee; form notes for each tranche; and legal opinions from Jones Day under French and New York law.
Sanofi (SNY) furnished a Form 6-K noting it has attached a press release dated October 22, 2025. The release reports that efdoralprin alfa met all primary and key secondary endpoints in a phase 2 study for alpha-1 antitrypsin deficiency (AATD) emphysema. This update signals a positive clinical milestone for the program and supports continued development based on the study’s predefined goals.
The filing itself provides no additional trial data beyond the headline result. Readers seeking design details, specific endpoints, or safety and efficacy metrics should refer to Exhibit 99.1, which contains the full press release.
Sanofi S.A. launched a primary debt offering of $500,000,000 floating rate notes due 2027, $500,000,000 floating rate notes due 2028, $400,000,000 3.750% notes due 2027, $400,000,000 3.800% notes due 2028, and $1,200,000,000 4.200% notes due 2032. Interest begins accruing on November 3, 2025.
The floating notes pay Compounded SOFR plus 0.460% (2027) or 0.540% (2028) with quarterly payments; fixed notes pay semiannually. Fixed tranches feature make‑whole redemption prior to defined par call dates, and par redemption thereafter; floaters are not redeemable before maturity except for tax events. The notes are unsecured, unsubordinated, not listed, and issued in $2,000 minimums.
Gross pricing reflected modest underwriting discounts, and net proceeds are approximately $2,986,198,000, intended for general corporate purposes.
Sanofi furnished a Form 6-K noting a press release titled “Sanofi successfully prices USD 3 billion of bond issue.” The filing indicates the company priced a USD 3 billion bond and includes the press release as Exhibit 99.1.
The press release is dated October 28, 2025, and is incorporated by reference in the submission.
Sanofi (SNY) filed a preliminary 424(b)(5) prospectus supplement to issue multiple tranches of unsecured, unsubordinated notes, including floating‑rate series tied to Compounded SOFR and fixed‑rate series. The notes rank equally with Sanofi’s other unsecured debt, are not subject to a sinking fund, and will not be listed on an exchange.
The floating‑rate notes reset quarterly at Compounded SOFR plus a margin and pay interest quarterly; the fixed‑rate notes pay interest semi‑annually. Interest begins accruing in 2025 with first payments in 2026. Optional redemption for fixed‑rate tranches includes a make‑whole call and a par call window, and all notes include tax redemption provisions. Minimum denominations are $2,000 and integral multiples of $1,000, delivered in book‑entry form through DTC, Euroclear and Clearstream. Sanofi intends to use net proceeds for general corporate purposes.
Sanofi furnished a Form 6‑K providing H1 2025 condensed consolidated results and updates. The company lost control of Opella on April 30, 2025; from May 1, 2025 OPAL JV Co is accounted for using the equity method. H1 operating cash flows reflect routine items, including income tax paid of €1,355 million, interest paid of €206 million, and interest received of €170 million.
Financing and liabilities were active across the period. As of June 30, 2025, current other bank borrowings included €4,535 million related to the US commercial paper program and €230 million related to the French program, while a financing cash‑flow line mainly comprised the US commercial paper program of €3,353 million (vs €6,060 million in H1 2024). Net debt metrics exclude lease liabilities of €1,776 million. The liability for royalties payable to Sobi on US Beyfortus net sales was €1,756 million, with nominal payments estimated at €1,027 million within one to five years and €2,293 million thereafter. The period included impairment losses of €210 million linked to R&D projects, a €17 million tax expense from Pillar Two, and an €88 million tax expense tied to the gain on the Opella deconsolidation.
Sanofi furnished a Form 6-K for October 2025, providing an update via an attached press release. Exhibit 99.1 is titled “Q3: continued sales and earnings progress” and is dated October 24, 2025. This filing shares the company’s quarterly narrative through that press release.
The report was signed on October 24, 2025 by Alexandra Roger, Head of Legal Corporate & Finance. Readers can reference Exhibit 99.1 for Sanofi’s Q3 themes around sales and earnings performance.
Sanofi furnished a Form 6-K listing recent company press releases from October 17–20, 2025. The exhibits cover: an EU regulatory review update for Rezurock in chronic graft-vs-host disease; a CHMP recommendation for EU approval of Wayrilz to treat immune thrombocytopenia; new data showing Sanofi’s high-dose influenza vaccine provided superior protection for older adults against hospitalization versus standard-dose; ESMO phase 2 findings for AlphaMedix supporting first-in-class potential in gastroenteropancreatic neuroendocrine tumors; and Tzield being accepted for expedited review in the US through the FDA Commissioner’s National Priority Voucher pilot program.
The filing compiles these updates for investors and incorporates the press releases by reference.
Sanofi furnished a Form 6-K announcing a press release dated October 8, 2025. The release states that AlphaMedixTM (212Pb-DOTAMTATE) achieved all primary efficacy endpoints in a phase 2 study, demonstrating clinically meaningful benefits in patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs). This update highlights mid-stage clinical results disclosed via an attached exhibit.
Sanofi reported two corporate developments in an exhibit list attached to its Form 6-K. A press release dated September 23, 2025, states that Sanofi's investigational medicine SAR446268 received U.S. Fast Track designation for the treatment of non-congenital myotonic dystrophy type 1, signaling accelerated regulatory review for that indication. A separate press release dated September 24, 2025, states Sanofi is committing an additional $625 million to Sanofi Ventures to boost investments in biotech and digital health innovation.
Both items are presented as exhibits to the current report and indicate near-term regulatory and strategic investment activity explicitly disclosed by the company.